Electrical brain networks before and after transcranial pulsed shockwave stimulation in Alzheimer's patients
- PMID: 39192004
- PMCID: PMC11872817
- DOI: 10.1007/s11357-024-01305-x
Electrical brain networks before and after transcranial pulsed shockwave stimulation in Alzheimer's patients
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder that dramatically affects cognitive abilities and represents the most common cause of dementia. Currently, pharmacological interventions represent the main treatment to deal with the symptoms of AD; however, alternative approaches are readily sought. Transcranial pulse stimulation (TPS) is an emerging non-invasive neuromodulation technique that uses short, repetitive shockwaves with the potential to provide a wide range of vascular, metabolic, and neurotrophic changes and that has recently been shown to improve cognitive abilities in AD. This exploratory study aims to gain insight into the neurophysiological effect of one session of TPS in AD as reflected in electroencephalographic measures, e.g., spectral power, coherence, Tsallis entropy (TE), and cross-frequency coupling (cfc). We document changes in power (frontal and occipital), coherence (frontal, occipital and temporal), and TE (temporal and frontal) as well as changes in cfc (parietal-frontal, parietal-temporal, frontal-temporal). Our results emphasize the role of electroencephalographic measures as prospective markers for the neurophysiological effect of TPS.
Keywords: Alzheimer’s disease; Coherence; Cross-frequency-coupling; Electroencephalogram, ultrasound, shock waves; Non-pharmacological, intervention; Power; Tsallis entropy.
© 2024. The Author(s).
Conflict of interest statement
Declarations. Ethical approval and consent to participate: This EEG study was conducted in accordance with the Ethics Committee of the regional Medical Chamber (Ärztekammer Nordrhein, Nr. 2021137). Patients signed a written consent for participation. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. Consent for publication: The authors have the right to publish the data expressed in the manuscript. Competing interests: LW has previously received funding grants and institutional support from the German Research Foundation, Hilde-Ulrichs-Stiftung für Parkinsonforschung, and the ParkinsonFonds Germany, BMBF/ERA-NETNEURON, DFG Forschergruppe (FOR1328), Deutsche Parkinson Vereinigung (DPV), Forschungskommission, Medizinische Fakultät, HHU Düsseldorf, UCB; Medtronic, UCB, Teva, Allergan, Merz, Abbvie, Roche, Bial, Merck, Novartis, Desitin, Spectrum. Lars Wojtecki owns stock in company BioNTech SE. Lars Wojtecki is a consultant to the following companies: TEVA, UCB Schwarz, Desitin, Medtronic, Abbott/Abbvie, MEDA, Boehringer I, Storz Medical, Kyowa Kirin, Guidepoint, Merck, Merz, Synergia, BIAL, Zambon, Sapio Life, STADA, Inomed, Vertanical. The other authors have no competing interests to declare.
Figures






Similar articles
-
Quantitative EEG After Brain Stimulation and Cognitive Training in Alzheimer Disease.J Clin Neurophysiol. 2017 Jan;34(1):49-54. doi: 10.1097/WNP.0000000000000301. J Clin Neurophysiol. 2017. PMID: 28045857
-
Transcranial pulse stimulation in Alzheimer's disease.CNS Neurosci Ther. 2024 Feb;30(2):e14372. doi: 10.1111/cns.14372. Epub 2023 Jul 20. CNS Neurosci Ther. 2024. PMID: 37469252 Free PMC article.
-
The emerging field of non-invasive brain stimulation in Alzheimer's disease.Brain. 2024 Dec 3;147(12):4003-4016. doi: 10.1093/brain/awae292. Brain. 2024. PMID: 39562009 Free PMC article. Review.
-
A retrospective analysis of ultrasound neuromodulation therapy using transcranial pulse stimulation in 58 dementia patients.Psychol Med. 2025 Mar 4;55:e70. doi: 10.1017/S0033291725000406. Psychol Med. 2025. PMID: 40033713 Free PMC article.
-
Transcranial electrical stimulation as a therapeutic strategy for Alzheimer's disease: Current uses and challenges.J Alzheimers Dis. 2025 Mar;104(2):297-305. doi: 10.1177/13872877251315777. Epub 2025 Feb 24. J Alzheimers Dis. 2025. PMID: 39994987 Review.
Cited by
-
Commentary: Treating Diseases from Alzheimer's to Parkinson's Using Transcranial Pulse Stimulation: Mechanistic Insights, Recent Evidence, and Ethical Considerations.NeuroSci. 2025 Jun 17;6(2):56. doi: 10.3390/neurosci6020056. NeuroSci. 2025. PMID: 40559217 Free PMC article.
-
Transcranial Pulse Stimulation in Alzheimer's: Long-Term Feasibility and a Multifocal Treatment Approach.Brain Sci. 2025 Aug 1;15(8):830. doi: 10.3390/brainsci15080830. Brain Sci. 2025. PMID: 40867162 Free PMC article.
-
Electroencephalographic Biomarkers for Neuropsychiatric Diseases: The State of the Art.Bioengineering (Basel). 2025 Mar 14;12(3):295. doi: 10.3390/bioengineering12030295. Bioengineering (Basel). 2025. PMID: 40150759 Free PMC article. Review.
-
Transcranial ultrasound stimulation in neuromodulation: a bibliometric analysis from 2004 to 2024.Front Neurosci. 2025 May 13;19:1595061. doi: 10.3389/fnins.2025.1595061. eCollection 2025. Front Neurosci. 2025. PMID: 40433495 Free PMC article.
-
Targeting Neural Oscillations for Cognitive Enhancement in Alzheimer's Disease.Medicina (Kaunas). 2025 Mar 20;61(3):547. doi: 10.3390/medicina61030547. Medicina (Kaunas). 2025. PMID: 40142358 Free PMC article. Review.
References
-
- van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21. 10.1056/NEJMoa2212948. - PubMed
-
- Mullard A. Landmark Alzheimer’s drug approval confounds research community. Nature. 2021;594:309–10. 10.1038/d41586-021-01546-2. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical